Welcome to our dedicated page for Evotec SE American Depositary Shares news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec SE American Depositary Shares stock.
Evotec SE, headquartered in Hamburg, Germany, is a leading global drug discovery and development company. Specializing in providing comprehensive solutions to pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations, Evotec is renowned for its extensive capabilities in therapeutic areas such as central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health.
Evotec’s core business is divided into two main segments: Shared R&D and Just-Evotec Biologics. The Shared R&D segment, making up approximately 80% of the company's sales, offers drug discovery and manufacturing services on a fee-for-service basis. It also engages in integrated drug discovery collaborations leveraging proprietary, internally-developed assets. Just-Evotec Biologics, accounting for about 20% of sales, provides contract development and manufacturing (CDMO) services for biologics.
With a workforce of over 5,000 employees, Evotec operates 18 production sites mainly across Europe and the United States. In recent years, the company has made significant strides in forming strategic alliances and collaborations, such as the recent partnership with Claris Ventures and Variant Bio, aimed at accelerating the development of innovative therapeutics.
Evotec’s multimodal platform combines cutting-edge technologies, data, and scientific expertise to drive the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. The company’s integrated R&D network includes partnerships with all Top 20 Pharma companies and over 800 biotech companies, academic institutions, and other healthcare stakeholders. This robust network facilitates the co-creation of a world-leading pipeline of over 200 proprietary and co-owned R&D projects, ranging from early discovery to clinical development.
Recent achievements by Evotec include the successful Clinical Trial Application (CTA) for IAMA Therapeutics’ lead program IAMA-6 and the strategic collaboration with Janssen for immune-based therapies. Additionally, Evotec has expanded its relationship with Bristol Myers Squibb in neurodegeneration and targeted protein degradation.
Financially, Evotec has demonstrated resilience despite macroeconomic challenges and a substantial cyber-attack in 2023. The company reported a 4% increase in revenues, reaching €781.4 million in 2023, driven by new collaborations and the strong performance of Just-Evotec Biologics.
As of 2024, Evotec continues to focus on sustainable and profitable growth, optimizing its operations to meet evolving market demands. The company is committed to advancing its mission of discovering and developing effective therapeutics that address unmet medical needs globally.
Evotec SE announced a contract with the U.S. Department of Defense valued up to $49.9 million for the rapid development of monoclonal antibody drug prototypes targeting plague. Under this contract, Just - Evotec Biologics will advance mAb prototypes from initial discovery to Phase I clinical trials using its J.DESIGN platform, which integrates AI and machine learning. The goal is to produce effective medical countermeasures against plague, enhancing national security. The work will take place at Evotec's Redmond, Washington facility, part of the DOD's Advanced Development and Manufacturing network.
Evotec has begun construction of its J.POD ® biologics manufacturing facility in Toulouse, France, expected to be operational in H2 2024. This facility will utilize advanced J.POD ® technology to enhance clinical and commercial manufacturing capacity for biologics, addressing challenges in traditional manufacturing methods. The project is backed by funding from the French government and the Occitanie Region and is anticipated to create over 150 high-skill jobs in the area.
Evotec operates globally and focuses on the development of therapeutics across various medical areas.
Evotec SE has announced its acquisition of Central Glass Germany GmbH from Central Glass Co. Ltd., enhancing its drug substance manufacturing capabilities. The fully operational facility in Halle/Westphalia, with a team of ~60 chemists, is EU cGMP certified, covering over 5,000 square meters. This strategic move aligns with Evotec's commitment to rare diseases and precision medicine, aiming for earnings accretion by 2023/24. The contract, signed on August 24, 2022, was at a purchase price of €1, and the transaction is set to close on November 1, 2022.
Evotec SE and Alpine Immune Sciences have expanded their partnership to develop a commercial manufacturing process for ALPN-303, a dual BAFF/APRIL inhibitor. This collaboration builds on their ongoing first-in-human program initiated in 2020, with Evotec providing drug substance materials for clinical studies. The enhanced contract will utilize Evotec's J.DESIGN technology platform in Redmond, Washington, aiming to improve outcomes for patients with systemic lupus erythematosus and other autoimmune diseases.
Evotec SE will release its financial results for the first half of 2022 on August 11, 2022. A conference call will be held at 02:00 PM CEST to discuss the outcomes and company performance. Dial-in details are provided for various countries, and a webcast with presentation slides will also be available on their website. Evotec is a life science company focused on developing innovative therapeutics across multiple therapeutic areas, boasting over 200 proprietary projects in its pipeline.
Boehringer Ingelheim, Evotec, and bioMérieux have formed a joint venture named Aurobac Therapeutics SAS to combat Antimicrobial Resistance (AMR). Funded by Boehringer with 30 million EUR and 5 million EUR each from Evotec and bioMérieux, the venture aims to develop new antimicrobials and diagnostics. AMR poses a significant global health threat, with antibiotic-resistant infections causing around 1.27 million deaths annually. Aurobac seeks to implement precision medicine approaches and new economic models to enhance treatment strategies.
Evotec SE held its virtual Annual General Meeting (AGM) on June 22, 2022, with 65.68% of registered shareholders participating. All agenda items were adopted, including the election of Camilla Macapili Languille to the Supervisory Board, succeeding Kasim Kutay. The AGM approved the creation of Authorized Capital 2022 amounting to 20% of the share capital and a revised remuneration system for the Management Board, receiving 94.48% approval. The meeting also reaffirmed BDO AG as auditors for the fiscal year 2022.
Exscientia announced positive results from its Phase 1 healthy volunteer study of EXS-21546, a selective A2A receptor antagonist. The study confirmed potency and selectivity with low CNS exposure, supporting a Phase 1b/2 study in patients with high adenosine signature solid tumors, anticipated to start in the second half of 2022. The trial showed dose-dependent effects and was well-tolerated, with only one serious adverse event recorded that resolved without intervention. These findings enhance the potential for EXS-21546 to improve immunomodulatory treatments in cancer therapy.
Evotec SE has announced a strategic drug discovery collaboration with Janssen Pharmaceutica NV to explore novel therapeutic candidates via its TargetAlloMod platform. This partnership aims for high-potential cell surface drug targets within various therapeutic areas. Besides research funding, Evotec stands to gain approximately €210 million per project in success-based milestones and tiered royalties on resultant products. The collaboration highlights Evotec's innovative strengths and commitment to delivering effective therapeutics.
Evotec has announced the acquisition of Rigenerand Srl, a leading cell technology company, for €23 million. This move enhances Evotec's cell therapy platform by integrating high-quality cGMP manufacturing capabilities. Rigenerand, based in Italy, operates a state-of-the-art facility focused on cell therapy manufacturing. While initial revenue contributions are expected to be modest, the acquisition will strengthen Evotec's capabilities to secure new partnerships in the cell therapy sector. Both companies aim to leverage their combined expertise to advance innovative cell therapies.
FAQ
What is the current stock price of Evotec SE American Depositary Shares (EVO)?
What is the market cap of Evotec SE American Depositary Shares (EVO)?
What is Evotec SE?
What are Evotec's main business segments?
Who are Evotec's partners?
What recent collaborations has Evotec entered into?
How many employees does Evotec have?
What are Evotec's key therapeutic areas?
What financial performance did Evotec report in 2023?
What are the future goals of Evotec?
What is Just-Evotec Biologics?